IDEXX Laboratories (NASDAQ:IDXX) EVP Michael Erickson Sells 5,371 Shares of Stock

IDEXX Laboratories, Inc. (NASDAQ:IDXX) EVP Michael Erickson sold 5,371 shares of the business’s stock in a transaction on Tuesday, February 17th. The shares were sold at an average price of $627.38, for a total transaction of $3,369,657.98. Following the sale, the executive vice president directly owned 12,693 shares in the company, valued at $7,963,334.34. This trade represents a 29.73% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

IDEXX Laboratories Stock Performance

IDXX stock traded down $0.71 during midday trading on Friday, reaching $630.02. The stock had a trading volume of 55,484 shares, compared to its average volume of 491,993. The firm has a fifty day simple moving average of $679.11 and a two-hundred day simple moving average of $669.15. IDEXX Laboratories, Inc. has a 52-week low of $356.14 and a 52-week high of $769.98. The company has a debt-to-equity ratio of 0.23, a quick ratio of 0.90 and a current ratio of 1.23. The stock has a market cap of $50.31 billion, a PE ratio of 48.27, a P/E/G ratio of 3.86 and a beta of 1.67.

IDEXX Laboratories (NASDAQ:IDXX) last posted its quarterly earnings results on Monday, February 2nd. The company reported $2.92 earnings per share for the quarter, missing the consensus estimate of $2.93 by ($0.01). IDEXX Laboratories had a net margin of 24.62% and a return on equity of 69.78%. The firm had revenue of $1.09 billion for the quarter, compared to analysts’ expectations of $1.07 billion. During the same quarter in the previous year, the firm posted $2.53 EPS. The firm’s revenue for the quarter was up 14.3% compared to the same quarter last year. IDEXX Laboratories has set its FY 2026 guidance at 14.290-14.800 EPS. As a group, equities research analysts anticipate that IDEXX Laboratories, Inc. will post 11.93 EPS for the current year.

Analyst Ratings Changes

Several research firms have recently commented on IDXX. Barclays dropped their price objective on shares of IDEXX Laboratories from $850.00 to $800.00 and set an “overweight” rating on the stock in a report on Thursday, February 5th. Piper Sandler decreased their target price on shares of IDEXX Laboratories from $775.00 to $750.00 and set a “neutral” rating for the company in a research report on Monday, February 9th. Stifel Nicolaus set a $775.00 price target on shares of IDEXX Laboratories in a report on Monday, November 3rd. Morgan Stanley increased their price target on IDEXX Laboratories from $765.00 to $805.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 4th. Finally, Weiss Ratings cut IDEXX Laboratories from a “buy (b-)” rating to a “hold (c+)” rating in a report on Thursday, January 29th. Seven investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat, IDEXX Laboratories currently has a consensus rating of “Moderate Buy” and an average price target of $783.33.

Hedge Funds Weigh In On IDEXX Laboratories

Several institutional investors and hedge funds have recently modified their holdings of IDXX. Empowered Funds LLC grew its holdings in IDEXX Laboratories by 6.6% in the first quarter. Empowered Funds LLC now owns 1,538 shares of the company’s stock valued at $646,000 after purchasing an additional 95 shares during the period. Sivia Capital Partners LLC purchased a new position in shares of IDEXX Laboratories during the 2nd quarter valued at approximately $265,000. Harbour Investments Inc. grew its stake in IDEXX Laboratories by 27.3% in the 2nd quarter. Harbour Investments Inc. now owns 98 shares of the company’s stock valued at $53,000 after acquiring an additional 21 shares during the period. Mutual Advisors LLC acquired a new stake in IDEXX Laboratories in the 2nd quarter valued at $244,000. Finally, Nordea Investment Management AB increased its holdings in IDEXX Laboratories by 4.7% in the 2nd quarter. Nordea Investment Management AB now owns 8,057 shares of the company’s stock worth $4,298,000 after acquiring an additional 361 shares in the last quarter. Hedge funds and other institutional investors own 87.84% of the company’s stock.

About IDEXX Laboratories

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.